Compare Expedia Group Inc (EXPE) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Repligen Corporation Common Stock — how do they compare? Expedia Group Inc trades at $275.05 (market cap $32.97B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Expedia Group Inc is far larger — about 2.9× Repligen Corporation Common Stock's market cap, and Expedia Group Inc pays a 0.7% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 47 Days and Repligen Corporation Common Stock for 0 Days on average.
| EXPE | RGEN | |
|---|---|---|
Market Cap | $32.97B | $11.31B |
Volume | 1,375,250 | 1,216,919 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $194.57 |
52-Week Low | $188.51 | $102.87 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | $31.53B | $11.20B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $273.44, up 1.85% with strong technical momentum above key support levels. The company demonstrates robust fundamentals with consistent earnings beats, 90% gross margins, and improving cash flow generation. Recent news highlights competitive threats from AI shopping agents but also strong B2B booking growth outpacing peers. Analyst consensus remains divided with a $335 price target representing 22% upside potential.
Expedia presents a compelling growth story with solid execution but faces significant AI disruption risks. The stock offers attractive valuation multiples and strong profitability metrics, though competitive pressures from Meta's Muse AI agent and ongoing layoffs create near-term uncertainty. Institutional positioning remains mixed with recent downgrades offset by positive earnings momentum.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
